SEARCH RESULTS FOR:
Danny Callow
CEO, AFRICAN GOLD GROUP (AGG)
African Gold Group explains its ambitions in West Africa where it’s Kobada gold mine is under construction.
Eduardo Cossio Chirinos
CEO, INCIMMET
INCIMMET is exporting its services to the mining industry from Peru throughout Latin America.
Darío Barros Izquierdo
GENERAL MANAGER, ECHEVERRIA IZQUIERDO MONTAJES INDUSTRIALES
Chile Mining 2020 EXPOMIN Official Investment Guide
Echeverría Izquierdo Montajes Industriales is a leading construction firm operating in Chile’s mining industry.
Chris Frostad
PRESIDENT & CEO, PUREPOINT URANIUM GROUP
With stronger uranium fundamentals, activity in the Athabasca basin is set to increase.
Ciro Marino
CEO, ABIQUIM
Abiquim discusses the outlook for Brazil’s chemical industry and the implications of the government’s economic reforms, including the ‘New Gas Market’.
João Parolin
CEO, OXITENO
Oxiteno identifies good opportunities both at home in Brazil and elsewhere, despite the pandemic and Brazil’s faltering recovery.
Fanon Beya
DIRECTOR, CONNEXAFRICA
ConnexAfrica is a new entity resulting from its separation from Comexas Afrique and provides logistics services for miners in the DRC.
Brian Larocque
GENERAL MANAGER, CHILE/ HARD-LINE
Chile Mining 2020 EXPOMIN Official Investment Guide
Hard-Line in Chile comments on the adoption of automation and tele-operated trucks and machinery by mining companies.
Paul Hennessey
SENIOR VICE PRESIDENT – OPERATIONS, QUALITY AND TECHNICAL SERVICES, ADVANTICE HEALTH
United States Biopharmaceuticals 2020
Advantice Health provides consumer health care products and is focused on building a number of brands.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
